Can-Fite BioPharma, a biotechnology company, recently announced a breakthrough in the inhibition of pancreatic cancer. Their drug candidate, Namodenoson, was shown to inhibit the growth of pancreatic cancer cells in preclinical studies. In addition, Can-Fite scientists have discovered the molecular mechanism of action for this inhibition.
The study found that Namodenoson activated the A3 adenosine receptor (A3AR) on the surface of pancreatic cancer cells. This led to the inhibition of the AKT and ERK signaling pathways, which are critical for the growth and survival of cancer cells. The activation of the A3AR also triggered the release of calcium ions, which further suppressed the growth of the cancer cells.
Also Read:- Understanding the Turbine Market: Trends, Growth Factors, and Future Prospects
- Houston Astros Suffer Embarrassing Shutout Loss Against San Francisco Giants
The discovery of the molecular mechanism of action is a significant step forward for Can-Fite. It not only validates the efficacy of Namodenoson but also provides insight into how it works. This information can be used to develop more effective therapies for pancreatic cancer and other types of cancer that rely on the same signaling pathways.
Can-Fite BioPharma is now moving forward with clinical trials of Namodenoson for the treatment of pancreatic cancer. The company plans to conduct a Phase II clinical trial in the United States and Israel. The trial will enroll patients with locally advanced or metastatic pancreatic cancer who have failed at least one prior line of therapy. The primary endpoint of the trial is overall survival.
In addition to pancreatic cancer, Can-Fite BioPharma is exploring the use of Namodenoson for the treatment of liver cancer, nonalcoholic steatohepatitis (NASH), and other indications. The company is also developing other drug candidates that target the A3AR for the treatment of autoimmune and inflammatory diseases.
The discovery of the molecular mechanism of action for Namodenoson is a significant milestone for Can-Fite BioPharma. It not only provides insight into how the drug candidate works but also validates its efficacy in preclinical studies. The company is now moving forward with clinical trials, which will determine the drug's safety and efficacy in humans. If successful, Namodenoson could be a breakthrough therapy for pancreatic cancer and other indications.
Keywords: Can-Fite BioPharma, Namodenoson, pancreatic cancer, molecular mechanism of action, clinical trials, A3 adenosine receptor, AKT signaling pathway, ERK signaling pathway, calcium ions, liver cancer, nonalcoholic steatohepatitis, autoimmune diseases, inflammatory diseases.
Read More:- How to Maximize Your Savings with Higher Interest Rates
- Lionel Messi's Future: Will He Move to MLS or Stay in Europe?
Thanks for Visiting Us – Mirror7News.com
Post a Comment